✦ LIBER ✦

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

✍ Scribed by Sohn, Sang Kyun; Oh, Suk Joong; Kim, Byung Soo; Ryoo, Hun Mo; Chung, Joo Seop; Joo, Young Don; Bang, Soo Mee; Jung, Chul Won; Kim, Dong Hwan; Yoon, Sung Soo; Kim, Ho; Lee, Hong Ghi; Won, Jong Ho; Min, Yoo Hong; Cheong, June Won; Park, Joon Seong; Eom, Ki Seong; Hyun, Myung Soo; Kim, Min Kyoung; Kim, Hawk; Park, Moo Rim; Park, Jinny; Kim, Chul Soo; Kim, Hyeoung Joon; Kim, Yeo Kyeoung; Park, Eun Kyung; Zang, Dae Young; Jo, Deog Yeon; Moon, Joon Ho; Park, Seon Yang

Book ID: 121237943
Publisher: Informa plc
Year: 2011
Tongue: English
Weight: 250 KB
Volume: 52
Category: Article
ISSN: 1042-8194
DOI: 10.3109/10428194.2011.563885

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trough imatinib plasma levels are associ

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

✍ Picard, S.; Titier, K.; Etienne, G.; Teilhet, E.; Ducint, D.; Bernard, M.-A.; La 📂 Article 📅 2006 🏛 American Society of Hematology 🌐 English ⚖ 81 KB

Cytogenetic and molecular responses to s

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

✍ Donna L. Forrest; Shannon Trainor; Ryan R. Brinkman; Michael J. Barnett; Donna E 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Imatinib dose escalation in two patients

Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response

✍ Edgar Faber; David Friedecký; Kateřina Mičová; Martina Divoká; Beata Katrincsáko 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 236 KB

Molecular responses at 3 and 6 months af

Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib

✍ Boquimpani, Carla; Schaffel, Rony; Biasoli, Irene; Bendit, Israel; Spector, Nels 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 715 KB